Thursday 16 October, 2025
Objectives: The tumor-growth model by Simeoni et al. [1] has been widely used to understand and characterize the drug effect…
Read morePoster: Oncology
Modeling Erlotinib and Gefitinib in Vitro Penetration through Multiple Layers of Epidermoid and Colorectal Human Carcinoma Cells
Thursday 16 October, 2025
Objective: Penetration of anticancer drug in tumor tissue is an important factor to achieve exposure of cancer cells to efficacious…
Read moreCharacterizing the dose-efficacy relationship for anti-cancer drugs using longitudinal solid tumor modeling
Thursday 16 October, 2025
Objectives: Dose escalation trials in oncology are aimed to identify the Maximum Tolerated Dose and by design, adverse events often…
Read moreModelling Irinotecan PK, efficacy and toxicities pre-clinically
Thursday 16 October, 2025
Objectives: Irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor, approved for use in colorectal cancer. Although CPT-11 shows anti-tumor activity…
Read moreA PK-PGx study of irinotecan: influence of genetic polymorphisms of xenoreceptors CAR (NR1I3) and PXR (NR1I2) on PK parameters
Thursday 16 October, 2025
Objectives: Irinotecan is an anticancer agent broadly used in the treatment of colorectal cancer. The main genetic factor associated with…
Read moreModeling tumor dynamics and overall survival in patients with low-grade gliomas treated with temozolomide.
Thursday 16 October, 2025
Objectives: To develop a model able to predict tumor size dynamics and overall survival (OS) in patients with low-grade gliomas…
Read moreCapecitabine: a pharmacokinetic model derived from its clinical use
Thursday 16 October, 2025
Objectives: Capecitabine, a fluorouracil (5FU) prodrug, has proven efficacy in those tumors in which fluoruracil is effective. To be active,…
Read moreThe Enhancement of Tumor Vaccine Efficacy by Immunotherapy
Thursday 16 October, 2025
Objectives: We highlight how immunotherapy might be used to overcome the effects of two immuno-regulatory agents exploited by cancer: regulatory…
Read moreThe influence of CYP2D6 genetic polymorphism on tamoxifen and its active metabolite exposure in breast cancer patients: preliminary results from a prospective, open-label trial.
Thursday 16 October, 2025
Objectives: Tamoxifen (Tam) treated patients with null or reduced CYP2D6 activity display low endoxifen exposure and thus might experience lower…
Read morePopulation Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients
Thursday 16 October, 2025
Objectives: Tamoxifen (Tam) is a pro-drug metabolized to endoxifen and other active metabolites through cytochromes (CYP) 2D6 and 3A4 pathways. Patients…
Read more